Phase 2 RCT: Psilocybin, a psychedelic compound, shows promise for the treatment of depression in a study with 59 patients
16 Apr, 2021 | 06:17h | UTCTrial of Psilocybin versus Escitalopram for Depression – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Magic mushroom compound performs as well as antidepressant in small study – Imperial College London AND First-of-its-kind study pits psilocybin against a common antidepressan – STAT AND Psilocybin Not Significantly Different from Escitalopram for Depression – NEJM Journal Watch AND Expert reaction to phase 2 trial comparing psilocybin and escitalopram for depression – Science Media Centre